The effect of differentiating and apoptotic agents on notch signalling pathway in hepatoblastoma

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 891-898

  Aktaş, Safiye ^a   Zadeoǧlulari, Zeynep ^a   Erçetin, Pinar ^a   Olgun, Nur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Hepatoblastoma; Notch

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; CBL PROTEIN; CISPLATIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTARABINE; DOXORUBICIN; HERMES ANTIGEN; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; ISOTRETINOIN; JAGGED1; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; RNA; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR PAX5;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFECT; HEPATOBLASTOMA; IMMUNOCYTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; RNA ISOLATION; SIGNAL TRANSDUCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CELL DIFFERENTIATION; CISPLATIN; CYTARABINE; DNA METHYLATION; DOXORUBICIN; GENE EXPRESSION PROFILING; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; ISOTRETINOIN; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TERATOGENS;

EID: 78149264308     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Herzog CE, Andrassy RJ, Eftekhari F: Childhood cancers: hepatoblastoma. Oncologist. 2000;5(6):445-53.
2. Tomlinson GE, Douglass EC, Pollock BH, et al: Cytogenetic evaluation of a large series of hepatoblastomas: Numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 2005;44:177-184.
3. Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, Veschi S, Cama A, Otte JB, Piantelli M, Mariani-Costantini R, Cetta F, Battista P: Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.Mod Pathol. 2008; 21(1):7-14.
4. Park WS, Oh RR, Park JY, et al: Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001;193:483-490
5. Monga SP, Mars WM, Pediaditakis P, et al: Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Metbeta- catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-2071.
6. Tomizawa M, Saisho H: Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol. 2006; 12(40):6531-5.
7. Czauderna P, Otte JB, Roebuck DJ, et al: Surgical treatment of hepatoblastoma in children. Pediatr Radiol 2006;36:187-191.
8. Dicken B, Bigam D, Shapiro A: Curative resection by superior hepatectomy for advanced hepatoblastoma facilitated by the presence of a large inferior right hepatic vein. HPB (Oxford). 2004;6(2):120-2.
9. Fuchs J, Rydzynski J, Von Schweinitz D, Bode U, Hecker H, Weinel P, Bürger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H: Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. 2002; 95(1):172-82.
10. Schnater JM, Köhner SE, Lamers WH, Schweinitz, Aronson DC: Where do we stand with hepatoblastoma? Cancer 2003; 98 (4): 668-677.
11. Douglass EC, Reynolds M, Finegold M, et al: Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study. J Clin Oncol 1993; 11:96-99.
12. Pritchard J, Brown J, Shafford E, et al: Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000; 18:3819-3828.
13. Sjölund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S, Nilsson E, Ljungberg B, Axelson A: Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008; 118(1): 217-228.
14. Zweidler-McKay PA: Notch signaling in pediatric malignancies. Curr Oncol Rep. 2008; 10(6):459-68.
15. Pahlman S, Stockhausen MT, Fredlund E, Axelson H: Notch signaling in neuroblastoma. Semin Cancer Biol. 2004; 14(5):365-73.
16. Allenspaeh EJ, Maillard I, Aster JC, Pear WS: Notch signaling in cancer. Cancer Biol Ther. 2002; 1(5):466-76.
17. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP: Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 2008; 14(10):2962-9.
18. Chiba S: Notch signaling in stem cell systems. Stem Cells. 2006; 24(11):2437-47.
19. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001; 6 Suppl 2:22-8.
20. Litten JB, Tomlinson GE: Liver tumors in children. Oncologist. 2008; 13(7):812-20.
21. Aktas S, Altun Z, Erbayraktar Z, Aygun N, Olgun N: Effect of cytotoxic agents and retinoic acid on Myc-N protein expression in neuroblastoma. Appl Immunohistochem Mol Morphol. 2010; 18(1):86-9.
22. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I: Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.Cancer. 1998; 83(11):2400-7.
23. Yu D, Wang Z, Zhu L, Chew EC: Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells. Chin Med J (Engl). 2003; 116(1):93-8. (Pubitemid 36432731)
24. Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ: Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol. 2009;40(6):843-53.
25. López-Terrada D, Gunaratne PH, Adesina AM, Pulliam J, Hoang DM, Nguyen Y, Mistretta TA, Margolin J, Finegold MJ: Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. 2009;40(6):783-94.